Yoon Suk Jung1, Chan Hyuk Park2, Jung Ho Park1, Eunwoo Nam3, Hang Lak Lee4. 1. Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. 3. Biostatistical Consulting and Research Lab, Medical Research Coordinating Center, Hanyang University, Seoul, Korea. 4. Division of Gastroenterology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: The efficacy of Helicobacter pylori eradication regimens may depend on the country where the studies were performed because of the difference in antibiotic resistance. We aimed to analyze the efficacy of H. pylori eradication regimens in Korea where clarithromycin resistance rate is high. METHODS: We searched for all relevant randomized controlled trials published until November 2016 that investigated the efficacy of H. pylori eradication therapies in Korea. A network meta-analysis was performed to calculate the direct and indirect estimates of efficacy among the eradication regimens. RESULTS: Forty-three studies were identified through a systematic review, of which 34 studies, published since 2005, were included in the meta-analysis. Among 21 included regimens, quinolone-containing sequential therapy for 14 days (ST-Q-14) showed the highest eradication rate (91.4% [95% confidence interval [CI], 86.9%-94.4%] in the intention-to-treat [ITT] analysis). The eradication rate of the conventional triple therapy for 7 days, standard sequential therapy for 10 days, hybrid therapy for 10-14 days, and concomitant therapy for 10-14 days was 71.1% (95% CI, 68.3%-73.7%), 76.2% (95% CI, 72.8%-79.3%), 79.4% (95% CI, 75.5%-82.8%), and 78.3% (95% CI, 75.3%-80.9%), respectively, in the ITT analysis. In the network meta-analysis, ST-Q-14 showed a better comparative efficacy than the conventional triple therapy, standard sequential therapy, hybrid therapy, and concomitant therapy. In addition, tolerability of ST-Q-14 was comparable to those regimens. CONCLUSION: In Korea, ST-Q-14 showed the highest efficacy in terms of eradication and a comparable tolerability, compared to the results reported for the conventional triple therapy, standard sequential therapy, hybrid therapy, and concomitant therapy.
BACKGROUND: The efficacy of Helicobacter pylori eradication regimens may depend on the country where the studies were performed because of the difference in antibiotic resistance. We aimed to analyze the efficacy of H. pylori eradication regimens in Korea where clarithromycin resistance rate is high. METHODS: We searched for all relevant randomized controlled trials published until November 2016 that investigated the efficacy of H. pylori eradication therapies in Korea. A network meta-analysis was performed to calculate the direct and indirect estimates of efficacy among the eradication regimens. RESULTS: Forty-three studies were identified through a systematic review, of which 34 studies, published since 2005, were included in the meta-analysis. Among 21 included regimens, quinolone-containing sequential therapy for 14 days (ST-Q-14) showed the highest eradication rate (91.4% [95% confidence interval [CI], 86.9%-94.4%] in the intention-to-treat [ITT] analysis). The eradication rate of the conventional triple therapy for 7 days, standard sequential therapy for 10 days, hybrid therapy for 10-14 days, and concomitant therapy for 10-14 days was 71.1% (95% CI, 68.3%-73.7%), 76.2% (95% CI, 72.8%-79.3%), 79.4% (95% CI, 75.5%-82.8%), and 78.3% (95% CI, 75.3%-80.9%), respectively, in the ITT analysis. In the network meta-analysis, ST-Q-14 showed a better comparative efficacy than the conventional triple therapy, standard sequential therapy, hybrid therapy, and concomitant therapy. In addition, tolerability of ST-Q-14 was comparable to those regimens. CONCLUSION: In Korea, ST-Q-14 showed the highest efficacy in terms of eradication and a comparable tolerability, compared to the results reported for the conventional triple therapy, standard sequential therapy, hybrid therapy, and concomitant therapy.
Authors: Byung Hak Jin; Byung Won Yoo; Jungsin Park; Jung Hye Kim; Jun Yeon Lee; Jae Soo Shin; Min Soo Park Journal: Eur J Clin Pharmacol Date: 2018-05-30 Impact factor: 2.953
Authors: Beom Jin Kim; Chang-Hun Yang; Hyun Joo Song; Seong Woo Jeon; Gwang Ha Kim; Hyun-Soo Kim; Tae Ho Kim; Ki-Nam Shim; Il-Kwun Chung; Moo In Park; Il Ju Choi; Ji Hyun Kim; Byung-Wook Kim; Gwang Ho Baik; Sok Won Han; Hyang Eun Seo; Woon Tae Jung; Jung Hwan Oh; Sang Gyun Kim; Jun Haeng Lee; Sue K Park; Byung-Joo Park; Bo Ram Yang; Joongyub Lee; Jae G Kim Journal: Helicobacter Date: 2019-08-01 Impact factor: 5.753
Authors: Youn I Choi; Jun Won Chung; Dong Kyun Park; Kyoung Oh Kim; Kwang An Kwon; Yoon Jae Kim; Ja Young Seo Journal: World J Gastroenterol Date: 2019-12-14 Impact factor: 5.742
Authors: Beom Jin Kim; Hyuk Lee; Yong Chan Lee; Seong Woo Jeon; Gwang Ha Kim; Hyun-Soo Kim; Jae Kyu Sung; Dong Ho Lee; Heung Up Kim; Moo In Park; Il Ju Choi; Soon Man Yoon; Sang Wook Kim; Gwang Ho Baik; Ju Yup Lee; Jin Il Kim; Sang Gyun Kim; Jayoun Kim; Joongyup Lee; Jae Gyu Kim; Jae J Kim Journal: Gut Liver Date: 2019-09-15 Impact factor: 4.519